Marc Tian, PhD, is affiliated with Teva Branded Pharmaceutical Products R&D, Inc., specializing in Real World Evidence Statistics in West Chester, Pennsylvania. The author's work focuses on schizophrenia and schizoaffective disorders, particularly the treatment journey and factors influencing the initiation of atypical long-acting injectable antipsychotic agents in young adults and early-phase patients. Marc Tian has published multiple articles in 2023 in Psychiatrist.com, collaborating frequently with John M. Kane, Jose M. Rubio, Mark Suett, Marko A. Mychaskiw, and Sangtaeck Lim.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
